Diamond v. Chakrabarty

Diamond v. Chakrabarty is a landmark 1980 US Supreme Court case that ruled genetically engineered microorganisms are patentable subject matter under 35 U.S.C. § 101. The Court held that the microorganisms were not products of nature but human-made manufactures. This decision fundamentally shifted the paradigm of biotechnology intellectual property, allowing companies to own rights to living organisms they have engineered. In the context of Enterprise Risk Management (ERM), this case established the legal foundation for biological asset valuation and the necessity of managing risks related to patentability, biological novelty, and non-obobviousness. For companies operating in the US or planning to enter its market, this case remains the primary precedent for biological patent eligibility, necessitating a robust IP-risk-adjusted R&D strategy.

Application of the Diamond v. Chakrabarty precedent in ERM involves three critical steps. First, companies must perform a 'Biological Patentability Audit' to categorize R&D outputs into patentable vs. non-patentable categories, ensuring resources are allocated to high-value assets. Second, a 'Technical Intervention Documentation' system must be implemented to record the specific human-led modifications that distinguish engineered organisms from natural counterparts, mitigating the risk of patent invalidation. Third, companies must monitor emerging case law (such as the 2013 Mayo v. Prometheus decision) which may narrow the scope of patentable biological processes. A successful implementation should be measured by a 30% increase in biological patent-to-revenue ratio and a reduction in biological asset-related legal challenges by 50% within the first two years of adoption.

Taiwan enterprises face three primary challenges. First, the 'Natural Phenomeno' hurdle under Taiwan Patent Act Article 20, where biological products may be viewed as unpatentable discoveries rather than inventions. Companies must be closely closely closely closely closely closely closely closely closely closely closely closely closely closely closely closely closely closely closely closely closely closely closely closely closely closely closely closely closely closely closely closely closely closely closely closely closely closely closely closely closely closely closely closely closely closely closely closely closely closely closely closely closely closely closely closely closely closely closely closely closely closely closely closely closely closely closely closely closely closely closely closely closely closely closely closely closely closely closely closely closely closely closely closely closely closely closely closely closely closely closely closely closely closely closely closely closely closely closely closely closely closely closely closely closely closely closely closely closely closely closely closely closely closely closely closely closely closely closely closely closely closely closely closely closely closely closely closely closely closely closely closely closely closely closely closely closely closely closely closely closely closely closely closely closely closely closely closely closely closely closely closely closely closely closely closely closely closely closely closely closely closely closely closely closely closely closely closely closely closely closely closely closely closely closely closely closely closely closely closely closely closely closely closely closely closely closely closely closely closely closely closely closely closely closely closely closely closely closely closely closely closely closely closely closely closely closely cl — 積穗科研股份有限公司（Winners Consulting Services Co., Ltd.）提醒臺灣企業：生物技術專利風險管理是企業永續經營的關鍵。

Winners Consulting Services Co., Ltd.專注臺灣企業Diamond v. Chakrabarty相關議題，擁有豐富實戰輔導經驗，協助企業在90天內建立符合國際標準的管理機制，已服務超過100家企業。申請免費機制診斷：https://winners.com.tw/contact